Outcomes of a Series of 237 Patients with Early Stage Peripheral NSCLC, Treated by SABR in a Single Institution Non-academic Setting

J Veeratterapillay,E Aynsley,G Kumar,S Masinghe,J Green,J Daniel,K Burke,A Greenhalgh,J Reynolds,C Huntley,J Bradley,C Peedell

doi:10.1016/j.clon.2018.02.035

Outcomes of a Series of 237 Patients with Early Stage Peripheral NSCLC, Treated by SABR in a Single Institution Non-academic Setting

J Veeratterapillay, E Aynsley + Show 10 more

https://doi.org/10.1016/j.clon.2018.02.035

Copy DOI

Journal: Clinical Oncology

Publication Date: Apr 30, 2018

Affiliation: South Tees Hospitals NHS Foundation Trust

#Early Stage NSCLC #Early NSCLC + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Introduction: Stereotactic radiotherapy (SABR) is a treatment option for patients with early stage NSCLC who are medically inoperable or who decline surgery. A meta-analysis of 40 SABR studies (4850 patients) showed overall survival at 1, 3 and 5 years of 83.4%, 56.6% and 41.2%, respectively. Most of these data come from large academic centres.

Full Text